Mednet Logo
Community

Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?

Community PollStarted

Would you consider the use of a GLP-1 RA in patients with obesity and known gastroparesis?

48 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Endocrinology · Brigham And Womens Hospital Endocrinology
Answered on

Short answer: yes. Gastroparesis is a well-known side effect of GLP-1 RA therapy. It is dose-dependent, so some patients may tolerate smaller doses but not the highest ones. A recent head-to-head trial of semaglutide vs tirzepatide in obesity (Aronne et al., PMID 40353578) found similar rates of gas...

Join for free or sign in to see the full answer